The AIDA project is organized in 6 work packages (WP's). Each work package has a work package leader, who is responsible for the particular work package.
Within the project AIDA there are several bodies involved in management of the project. The project has a coordinator, a project management office, an executive board and a general assembly. Also a scientific advisory board, a data safety monitoring board and a medical ethics review board have been established. Below you can find a description of the bodies and their responsibilities in the project.
The project coordinator, dr. Johan W. Mouton, is the intermediary between the European Commission and the Consortium as well as the supervisor of the overall progress of the project. Johan W. Mouton is medical microbiologist and heads the department of
bacteriology in the Department of Medical Microbiology of the Radboud University Nijmegen Medical Centre. He has been involved as
project leader and principal researcher in many national and international research projects. He is a work package co-ordinator principal researcher in the EU funded project SATURN. He is also a member of the steering committee of EUCAST and is secretary of the EPASG, the ESCMID Pharmacology of Antibiotics Study Group. Based on his experience, he will efficiently and openly coordinate the
overall progress of this collaborative project.
Project management office (PMO)
The project management office will be composed of the coordinator (dr. Johan W. Mouton), a project manager, a financial officer and a legal officer and will be responsible for the overall management of the consortium (WP6).
The Executive Board is a supervisory body for the execution of the project and shall report to and be accountable to the General Assembly. The Executive board will focus on integration of scientific efforts and will be composed of the coordinator (Mouton) and the Work Package Leaders, chosen to ensure the representation and integration of all lines of research:
WP 1 : M.Paul Main expertise:Controlled clinical trials, antibiotic management
WP 2 : S.Harbarth Main expertise: Controlled clinical trials,antimicrobial use and resistance
WP 3 : A.MacGowan Main expertise: Clinical trials, PK/PD, susceptibility testing
WP 4 : J.W.Mouton Main expertise: PK/PD, preclinical and clinical drug development, susceptibility testing
WP 5 : U.Theuretzbacher Main expertise: Clinical trials, Communication and dissemination in the area of Infectious diseases
The General Assembly is the ultimate decision-making body of the consortium and shall consist of one representative of each participant
organization. Each General Assembly member shall be deemed to be duly authorized to act on behalf of his/her organization. Each General Assembly member has one vote.
AIDA Consortium Members
At the time of application, the AIDA consortium consists of 14 institutes/organizations.
AIDA Work Packages Leaders (WP-Leaders)
To facilitate the management of the AIDA project, the work is structured in Work Packages, each of which has its own designated WP-Leader.
Scientific Advisory Board
At least three prominent scientists representing key aspects of the AIDA project will be invited to participate in the Scientific Advisory Board (SAB) of AIDA.
Data Safety Monitoring Board
An independent Data Safety Monitoring Board will be set up to monitor adverse events.
Medical Ethics Review Board
An independent Medical Ethics Review Board will be set up to review specific ethical questions.